Comprehensive Income (Loss), Net of Tax, Attributable to Parent of Oruka Therapeutics, Inc. from 31 Mar 2011 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
Summary
Oruka Therapeutics, Inc. quarterly and annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD history and change rate from 31 Mar 2011 to 30 Sep 2025.
  • Oruka Therapeutics, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending 30 Sep 2025 was $30,065,000, a 5% decline year-over-year.
  • Oruka Therapeutics, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending 30 Sep 2025 was $101,446,000.
  • Oruka Therapeutics, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2024 was $83,765,000.
  • Oruka Therapeutics, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2019 was $5,482,000, a 31% increase from 2018.
  • Oruka Therapeutics, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2018 was $7,931,000, a 57% increase from 2017.
Source SEC data
View on sec.gov
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Change (%)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Annual (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Annual Change (%)

Oruka Therapeutics, Inc. Quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $101,446,000 $30,065,000 -$1,442,000 -5% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $100,004,000 $24,595,000 -$2,352,000 -11% 01 Apr 2025 30 Jun 2025 10-Q 11 Aug 2025 2025 Q2
Q1 2025 $97,652,000 $20,964,000 -$13,887,000 -196% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $83,765,000 $25,822,000 01 Oct 2024 31 Dec 2024 10-K 06 Mar 2025 2024 FY
Q3 2024 $28,623,000 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $22,243,000 01 Apr 2024 30 Jun 2024 10-Q 11 Aug 2025 2025 Q2
Q1 2024 $7,077,000 06 Feb 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2019 $5,482,000 $1,226,000 +$263,000 +18% 01 Oct 2019 31 Dec 2019 10-K 18 Feb 2020 2019 FY
Q3 2019 $5,745,000 $1,156,000 +$437,000 +27% 01 Jul 2019 30 Sep 2019 10-Q 06 Nov 2019 2019 Q3
Q2 2019 $6,182,000 $1,436,000 +$680,000 +32% 01 Apr 2019 30 Jun 2019 10-Q 01 Aug 2019 2019 Q2
Q1 2019 $6,862,000 $1,664,000 +$1,069,000 +39% 01 Jan 2019 31 Mar 2019 10-Q 08 May 2019 2019 Q1
Q4 2018 $7,931,000 $1,489,000 +$2,707,000 +65% 01 Oct 2018 31 Dec 2018 10-K 18 Feb 2020 2019 FY
Q3 2018 $10,638,000 $1,593,000 +$2,838,000 +64% 01 Jul 2018 30 Sep 2018 10-Q 06 Nov 2019 2019 Q3
Q2 2018 $13,476,000 $2,116,000 +$3,402,000 +62% 01 Apr 2018 30 Jun 2018 10-Q 01 Aug 2019 2019 Q2
Q1 2018 $16,878,000 $2,733,000 +$1,595,000 +37% 01 Jan 2018 31 Mar 2018 10-Q 08 May 2019 2019 Q1
Q4 2017 $18,473,000 $4,196,000 +$61,000 +1.4% 01 Oct 2017 31 Dec 2017 10-K 27 Feb 2019 2018 FY
Q3 2017 $18,534,000 $4,431,000 +$247,000 +5.3% 01 Jul 2017 30 Sep 2017 10-Q 14 Nov 2018 2018 Q3
Q2 2017 $18,781,000 $5,518,000 -$1,631,000 -42% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018 2018 Q2
Q1 2017 $17,150,000 $4,328,000 -$687,000 -19% 01 Jan 2017 31 Mar 2017 10-Q 08 May 2018 2018 Q1
Q4 2016 $16,463,000 $4,257,000 -$1,089,000 -34% 01 Oct 2016 31 Dec 2016 10-K 22 Mar 2018 2017 FY
Q3 2016 $15,374,000 $4,678,000 -$1,864,000 -66% 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2017 2017 Q3
Q2 2016 $13,510,000 $3,887,000 -$1,168,000 -43% 01 Apr 2016 30 Jun 2016 10-Q 03 Aug 2017 2017 Q2
Q1 2016 $12,342,000 $3,641,000 -$897,000 -33% 01 Jan 2016 31 Mar 2016 10-Q 15 May 2017 2017 Q1
Q4 2015 $11,445,000 $3,168,000 01 Oct 2015 31 Dec 2015 10-K 21 Mar 2017 2016 FY
Q3 2015 $2,814,000 01 Jul 2015 30 Sep 2015 10-Q 14 Nov 2016 2016 Q3
Q2 2015 $2,719,000 01 Apr 2015 30 Jun 2015 10-Q 09 Aug 2016 2016 Q2
Q1 2015 $2,744,000 01 Jan 2015 31 Mar 2015 10-Q 11 May 2016 2016 Q1
Q1 2012 $1,407,000 +$799,000 +36% 01 Jan 2012 31 Mar 2012 10-Q 14 May 2012 2012 Q1
Q1 2011 $2,206,000 01 Jan 2011 31 Mar 2011 10-Q 14 May 2012 2012 Q1

Oruka Therapeutics, Inc. Annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $83,765,000 06 Feb 2024 31 Dec 2024 10-K 06 Mar 2025 2024 FY
2019 $5,482,000 +$2,449,000 +31% 01 Jan 2019 31 Dec 2019 10-K 18 Feb 2020 2019 FY
2018 $7,931,000 +$10,542,000 +57% 01 Jan 2018 31 Dec 2018 10-K 18 Feb 2020 2019 FY
2017 $18,473,000 -$2,010,000 -12% 01 Jan 2017 31 Dec 2017 10-K 27 Feb 2019 2018 FY
2016 $16,463,000 -$5,018,000 -44% 01 Jan 2016 31 Dec 2016 10-K 22 Mar 2018 2017 FY
2015 $11,445,000 01 Jan 2015 31 Dec 2015 10-K 21 Mar 2017 2016 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.